Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis | Synapse
February 6, 2024Open Access
Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis
Key Points
Key points are not available for this paper at this time.
Abstract
Our data strengthen the efficacy and safety profile of cefiderocol in CRAB infections.